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Abstract
Parkinson’s disease (PD) is a medical condition that has been known since ancient times. 
It is the second most common neurodegenerative disorder affecting approximately 1% 
of the population over 50 years. It is characterized by both motor and non-motor symp-
toms. Most of PD cases are sporadic while 5–10% cases are familial. Environment factors 
such as exposure to pesticides, herbicides and other heavy metals are expected to be 
the main cause of sporadic form of the disease. Mutation of the susceptible genes such 
as SNCA, PINK1, PARKIN, DJ1, and others are considered to be the main cause of the 
familial form of disease. Drosophila offers many advantages for studying human neuro-
degenerative diseases and their underlying molecular and cellular pathology. Shorter 
life span; large number of progeny; conserved molecular mechanism(s) among fly, mice 
and human; availability of many techniques, and tools to manipulate gene expression 
makes drosophila a potential model system to understand the pathology associated with 
PD and to unravel underlying molecular mechanism(s) responsible for dopaminergic 
neurodegeneration in PD—understanding of which will be of potential assistance to 
develop therapeutic strategies to PD. In the present review, we made an effort to discuss 
the contribution of fly model to understand pathophysiology of PD, in understanding 
the biological functions of genes implicated in PD; to understand the gene-environment 
interaction in PD; and validation of clues that are generated through genome-wide asso-
ciation studies (GWAS) in human through fly; further to screen and develop potential 
therapeutic molecules for PD. In nutshell, fly has been a great model system which has 
immensely contributed to the biomedical research relating to understand and addressing 
the pathology of human neurological diseases in general and PD in particular.
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1. Introduction
Parkinson’s disease (PD) is a medical condition that has been known about since ancient times in 
Indian and Chinese civilization [1, 2]. It is referred to as Kampavata in the ancient Indian medical 
system of Ayurveda (“kampa” means tremor in Sanskrit). An Egyptian papyrus from the twelfth 
century BC mentions a king drooling with age [3]. In Western medical literature, the tremor symp-
tom was described by the physician Galen in 175 AD [4]. In 1817, James Parkinson wrote an essay 
on “shaking palsy” based on six cases that he had observed in his own practice and on walks 
around his neighborhood. The essay was intended to encourage others to study the disease. This 
established the disease as a recognized medical condition. He termed this medical condition as 
“shaking palsy or paralysis agitans”. He published a detailed medical essay entitled “An Essay on 
the Shaking Palsy” where he described shaking palsy as “involuntary tremulous motion, with 
lessened muscular power, in parts not in action and even when supported; with a propensity to 
bend the trunk forwards, and to pass from a walking to a running pace: the senses and intellects 
being uninjured” [5]. The term “Parkinson’s disease” was coined in 1865 by William Sanders 
and later popularized by French neurologist Jean Martin Charcot [6]. Charcot and colleagues 
described the clinical symptoms of this disease, noting two prototypes: the tremorous and the 
rigid or akinetic form. They described the detailed arthritic changes, dysautonomia, and pain 
that can accompany Parkinson’s disease. He recognized that PD patients are not markedly weak 
and do not necessarily have tremor [7]. All these observations instigated the curiosity among the 
clinicians to understand this condition better with an aim to improve the patient’s quality of life.
2. Pathophysiology
Parkinson’s disease is the second most common neurodegenerative disorder affecting approx-
imately 1% of the population over 50 years [8]. A central pathological hallmark of PD is the 
selective loss of dopamine (DA) neurons in the substantia nigra pars compacta (SN). These dopa-
minergic neurons are required for proper motor function, and their deficiency manifests its char-
acteristic features: bradykinesia, tremors, and rigidity [9]. A second neuropathological hallmark 
of PD is the Lewy body (LB), which is a cytoplasmic spherical proteinaceous inclusion. LBs have 
been reported to contain various proteins including α-synuclein, ubiquitin, parkin, and neu-
rofilaments [10]. The mechanisms by which α-synuclein and other proteins aggregate to form 
Lewy pathology are uncertain, but may involve oxidative modifications and/or cross-linking. 
Although, the neurodegeneration of PD was considered to be confined to dopaminergic cell loss 
in the SN, cell loss, and neuropathology is found to occur in other parts as well including the 
locus coeruleus, raphe, nucleus basalis of Meynert, dorsal motor nucleus of the vagus, cerebral 
cortex, olfactory bulb, and autonomic nervous system [11]. Several non-motor symptoms such as 
sleep disturbances, constipation, cognitive decline, depression, fear, anxiety, bladder problems, 
weight changes, fatigue and loss of energy, hypotension, and sexual problems can be dominant 
and debilitating in a sizeable number of patients, affecting the quality of their life [12]. Till date, 
treatments address only the symptoms but they fail to stop the progression of the disease and PD 
patients continue to experience a higher mortality rate compared to the general population [13].
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2.1. Sporadic Parkinson’s disease
A sporadic PD has unknown cause with implication of environmental influence coupled 
with genetic factors. The pathology of PD therefore may be multifactorial involving gene 
and environment interactions. Studies indicate role of neurotoxicants or neuroprotective 
compounds in pathogenesis of nigrostriatal degeneration, supporting the concept of associa-
tion between the environment and PD [14]. Additionally, the identification of the mutated 
α-synuclein (SNCA) gene that cause familial PD [15] as a risk factor for sporadic disease [16] 
provides a genetic background for the disease. Studies suggest that rural people, well water 
consumption, pesticide use, and occupations like rural farming, mining, and welding have an 
increased risk of PD [17, 18]. Epidemiological studies suggest association of PD with environ-
mental toxic factors, primarily the mitochondrial complex I inhibitors such as rotenone [19]. 
Some other findings suggest that exposure to pesticide such as bipyridyl, organochlorine, and 
carbamate derivatives could contribute to PD [20].
2.2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Exploring the contribution of environmental exposure markedly advanced our understanding 
of the mechanisms involved in the development of PD. Initial evidence came from findings 
that subjects exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) developed 
PD-like symptoms [21]. MPTP was accidentally discovered in a synthesis process that went 
wrong, and, although it may have caused some problems in certain circles, today it represents 
the most important and most frequently used parkinsonian toxin applied in animal models. 
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a representative strong neurotoxin 
that has been recognized from several young drug addicts from Northern California devel-
oped severe parkinsonism [22]. Since then, environmental exposure to pesticides [23], poly-
chlorinated biphenyls [24], organic solvents [25], metals [26], and air pollutants [27] has been 
proposed to increase risk for PD.
2.3. Mechanism of MPTP neurotoxicity
Though the exact mechanism regarding the mode of MPTP toxicity is not known, it has been 
postulated that MPP+ entry into dopaminergic neurons is dependent on selective uptake by 
dopamine transporter localizing it and interfering into mitochondrial activity. MPTP is not 
toxic per se, but becomes toxic once it is converted to 1-methyl-4-phenyl-2,3-dihydropyridin-
ium (MPDP+) by action of monoamine oxidase B (MAO-B) in glial cells and serotoninergic 
neurons [28] followed by oxidation into 1-methyl-4-phenylpyridinium (MPP+), which is a 
highly toxic compound [29]. Then the dopamine transporter (DAT) carries it to dopaminergic 
neurons leading to its accumulation in cytoplasm and into synaptic vesicles by the vesicu-
lar monoamine transporter (VMAT). The driving force of mitochondrial membrane potential 
lets MPP+ enter these organelles, where it blocks complex I [30]. This leads to abnormally 
increased concentrations of the toxin to interfere with mitochondrial respiration by blocking 
the mitochondrial oxidation. Thus it results in impairment of ATP synthesis and involving in 
the generation of oxidative stress.
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2.4. Paraquat
Paraquat (1,1-dimethyl-4,4′-bipyridinium dichloride) is a quaternary nitrogen herbicide 
widely used for broadleaf weed control. It is a fast-acting, non-selective compound which 
destroys tissues of green plants on contact and by translocation with the plant. Significant 
damage to the brain was seen in individuals who died from paraquat intoxication [31]. For 
many years, experimental studies using paraquat were focusing on its effects on lung, liver, 
and kidney, probably because the toxicity induced by this herbicide in these organs is respon-
sible for death after acute exposure [32]. Epidemiological studies in agricultural communities 
have suggested an increased risk for PD due to paraquat use, raising the possibility that para-
quat could be an environmental parkinsonian toxin. This chemical causes extensive oxidative 
stress in mitochondria of the cell, resulting in the perturbation of biochemical processes, cell 
death, multi-organ failure, and neurodegenerative diseases [33].
It is still vague about how the molecular mechanism of paraquat leads to cell death. However, 
studies have shown that paraquat can trigger the sequential phosphorylation of c-Jun 
N-terminal kinase (JNK), c-Jun, and the activation of caspase-3 consequently leading to neu-
ronal death both in vitro and in vivo [34], suggesting that JNK signaling pathway contributes 
to paraquat-induced neurodegeneration.
2.5. Rotenone
Rotenone is a commonly used natural pesticide prepared from the roots of certain tropical plants, 
such as Derris elliptica. It is a classical high-affinity-specific inhibitor of mitochondrial complex 
I. This lipophilic compound crosses the blood-brain barrier rapidly and accumulates in subcel-
lular organelles such as mitochondria where it impairs oxidative phosphorylation by inhibiting 
complex I of the electron transport chain [35]. Postmortem studies implicated mitochondrial 
impairments [36], and epidemiological studies suggested an association with environmental 
toxins, in particular mitochondrial complex I inhibitors such as rotenone [37]. In vitro, rotenone 
has been shown to produce cell apoptosis, accumulation, and aggregation of α-synuclein and 
ubiquitin, oxidative damage, and endoplasmic reticulum stress [38, 39]. In a study in post mor-
tem idiopathic PD brain, the substantia nigra is seen to comprise of a strong inhibition of com-
plex I activity [40] suggesting this could be the cause of degeneration of dopaminergic neurons.
3. Familial/genetic Parkinson’s disease
Till date, 15 known genes and 21 loci have been identified for familial PD. Some of the genes 
are discussed further.
3.1. SNCA
In a study involving a large Italian family, Polymeropoulos and colleagues identified the mis-
sense mutations in the SNCA gene. Through a traditional linkage approach, they managed 
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to track the underlying genetic injury to an area located in the long arm of human chro-
mosome number 4 [41]. This discovery has been a FRAME shift in the genetic research of 
PD. A separate study showed that the α-synuclein protein is the main constituent of the Lewy 
body which is the pathological hallmark of PD [42]. These two vital research findings brought 
about a link between sporadic and familial forms of PD.
Five different missense mutations in SNCA have been implicated in PD namely A53T, A30P, 
E46K, H50Q, and G51D mutation. Clinically, early age onset of parkinsonism with a posi-
tive initial response to levodopa treatment are seen among patients with missense mutations 
but later on the disease progresses rapidly with dementia as a common feature. Eventually, 
appearance of cognitive decline, hallucinations, and fluctuations of consciousness in patients 
becomes clear. Histopathological study reveals an abundant LB pathology [43].
3.2. LRRK2
An association between apparent autosomal-dominant parkinsonism and chromosome 
number 12 was suggested by findings on a study involving a large Japanese family [44]. 
Later it was established that mutations in the gene LRRK2 lead to the basic genetic cause 
of chromosome number 12 linked PD [45]. The most frequent LRRK2 mutation is G2019S, 
detected in approximately 1% of sporadic and about 3–6% of familial PD cases [46]. R1441G 
is the second most common mutation after G2019S [47]. Most of the LRRK2 cases described 
demonstrate LB in the brainstem accompanied by loss of neurons in the SN. Only a minority 
of cases exhibit neurofibrillary tangle pathology, glial cytoplasmic inclusions, or neuronal 
nigral loss without LB [45].
3.3. PARKIN
An uncommon syndrome characterized by early dystonia and problems from levodopa 
treatment, osteotendinous hyperreflexia and comparatively slow motor progression was 
described in Japan in 1973, which is now known to be an autosomal-recessive juvenile par-
kinsonism (AR-JP) [48]. Mutations in parkin gene was identified as a cause of this condition 
[49]. AR-JP maps to the long arm of chromosome number 6 and linked to the markers D6S305 
and D6S253 [50]. It was found that the former is deleted in an AR-JP Japanese patient [51]. By 
positional cloning within this microdeletion, Kitada and colleagues isolated a cDNA clone of 
2960 bp with a 1395 bp open reading frame which code a 465 amino acid protein consisting 
of an N-terminal ubiquitin-like domain and RING domain having two RING finger motifs. 
The gene spans more than 500 kb and has 12 exons of which 5 exons (3–7) are found to be 
deleted in the patient. Also four other AR-JP unrelated patients have a deletion that affect 
only the exon 4. A 4.5 kb transcript expressed in various human tissues abundantly in the 
brain, including the substantia nigra, is shorter in brain tissue from one of the groups of 
exon 4 deleted patients. Therefore inferring that the mutations in this newly identified gene is 
responsible for the pathogenesis of AR-JP. In a number of families, PD is related with hetero-
zygous parkin mutations through an apparently dominant way of transmission, suggesting 
that the carriers of a sole parkin mutation might be at risk to develop the PD [52].
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3.4. DJ1
A homozygous deletion and a missense mutation in the Daisuke-Junko-1 (DJ-1) gene as a 
cause of autosomal-recessive early onset PD was identified [53]. A number of novel DJ-1 muta-
tions have been discovered in patients with early onset PD. However, these mutations are 
rare and can be found in only   ̴about 1% of early onset PD cases [54]. At the clinical level, the 
phenotype of DJ-1 subjects is the same as that of parkin and PINK1-related parkinsonism, with 
age at onset (AAO) usually around the mid-30s, good response to levodopa treatment, slow 
disease progression, and often focal dystonia such as blepharospasm [55]. However, the neu-
ropathology of DJ-1-linked parkinsonism still remains unidentified.
3.5. PINK1
Mutations in the phosphate and tensin homolog-induced Putative kinase 1 (PINK1) were initially 
identified in a Sicilian family with autosomal-recessive parkinsonism [56]. In most of PINK1 
mutations, the type of mutation seen is missense. However, mutations of copy number, genetic, 
and exonic rearrangements have been described [57]. In both the cases of familial and sporadic 
PD, investigation of mutation has recognized homozygous and compound heterozygous type 
PINK1 mutations. This raised the potential role on a single PINK1 heterozygous mutation to be 
a possible risk factor for PD [58]. In a number of families, PINK1 mutations have been associated 
with early onset PD and PINK1 mutations association in sporadic cases is about 2–4%. In a clini-
cal phenotype, this type of parkinsonism is quite comparable to those seen among patients with 
parkin and DJ-1 mutations. They display progressive levodopa-responsive disease gradually [57].
3.6. Vacuolar protein sorting-associated protein 35 (VPS35)
Mutation in VPS35 causes monogenic form of PD was described by using exome sequencing 
in two separate studies with identification of p.D620N mutation in VPS35 among the mem-
bers of a Swiss kindred with a late onset, autosomal-dominant PD [59]. An independent study 
published the identification of the p.D620N mutation in a large multi-generation Austrian PD 
family and in two additional families screened for VPS35 mutations [60]. The VPS35-linked 
families reportedly fulfill the London Brain Bank criteria for PD, but there are fairly limited 
clinical and pathological details on these cases.
3.7. ATPase (P-type) 13A2 (ATP13A2)
In a neuronal P-type ATPase gene, ATP13A2, a loss of function was initially described in a con-
sanguineous Jordanian family [61]. Clinically, the subjects showed a very early onset of the dis-
ease accompanied by rigid-akinetic phenotype with reduced resting tremor, pyramidal syndrome, 
progressive cognitive impairment, vertical gaze palsy, mini myoclonus, insomnia, and levodopa 
responsive [61]. Mutations of this gene mapping on chromosome 1p36 cause PD in atypical form 
which is known as Kufor-Rakeb syndrome [62]. Clinical phenotype of this early onset pallido-pyra-
midal syndrome varies in severity but only a handful of cases and families have been reported [63, 64].
3.8. PLA2G6
Homozygous mutations in phospholipase A2 gene (PLA2G6) located on chromosome 22q13.1 
was reported in three patients of two inbred Pakistani families. The phenotypes were associated 
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with cognitive and psychiatric problems and dystonic features, pyramidal syndrome [65]. 
In an Asian group with early onset recessive parkinsonism caused by compound heterozy-
gous mutations in PLA2G6, the phenotype reported were frontotemporal lobar atrophy and 
dementia [66]. The PLA2G6 gene encodes a protein of phospholipase A2 group VI (PLA2G6), 
which act as catalysis of fatty acids elimination from phospholipids and involved in maintain-
ing membrane phospholipids homeostasis [67].
3.9. UCH-L1
Missense mutations of gene coding for the ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), 
an ubiquitin recycling enzyme located on chromosome 4p14 was reported in a German fam-
ily with an autosomal-dominant transmission PD [68]. The phenotype of affected individuals 
was consistent with that of idiopathic PD. An epidemiological study suggested an association 
between the UCH-L1 gene S18Y variant and PD [69]. Overexpression of UCH-L1 gene upregu-
lated aggresomes formation through dysfunction of proteasome system [70].
3.10. HtrA2
Various studies indicate risk factor for parkinsonism due to loss of function of the gene encod-
ing Omi/high temperature requiring A2 mitochondrial protein (HtrA2) in German [71] and 
Belgians PD patients [72]. The serine protease Omi/HtrA2 is released from mitochondria and 
promotes apoptosis [73] and mutations of Omi/HtrA2 gene affect its protease activity linked 
to mitochondrial dysfunction [71, 72]. Although it acts independently of parkin, Omi/HtrA2 
functions in the PINK1/parkin pathway downstream of PINK1 [74]. These findings were not 
confirmed in Omi/HtrA2 knockout mutants in contrast to PINK1 or parkin null mutants [75].
3.11. EIF4G1
Mutations in the eukaryotic translation initiation factor 4-gamma (EIF4G1) was identified 
as a risk factor in a study of a northern French family with autosomal-dominant late onset 
parkinsonism on the chromosome 3q26-q28. Genomic analysis identified a heterozygous 
mutation in EIF4G1 which was confirmed subsequently in 2 PD patients and 2 Lewy body 
disease patients among 225 more patients [76]. Further, in all the affected members of another 
multiplex unrelated family, a pathogenic mutation was detected including in one unaffected 
86-year-old family member suggesting an incomplete penetrance [77].
4. Animal models of Parkinson’s disease
4.1. Criteria for modeling PD in animals
Being a neurodegenerative disorder, the prominent hall mark of PD is progressive loss of 
dopaminergic neurons in the Substantia niagra parse compacta (SNpc) [78]. Together with DA 
neurons, there is a loss of cholinergic neurons, serotonergic neurons, and nor adrenergic neu-
rons in the brain [79]. The prominent biomarker being aggregation of Lewy bodies in intra-
cytoplasmic space [80]. A combination of all these features shows the hallmark motor and 
non-motor symptom of PD.
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A suitable model for PD should show histopathologically characterizable progressive loss of DA 
neurons together with other neurons and significant reduction in DA level. Moreover, the onset 
of the disease should be in adulthood this should manifest in such a way that it would mimic 
the PD-affected human motor symptom such as bradykinesia, rigidity, postural instability, and 
resting tremor, with motor features being responsive to L-DOPA or any anti-PD drug therapy. 
Even though non human primate and mouse has been the traditional model of PD, because of 
low cost of maintenance, shorter life cycle, and defined neuropathological profile is making 
zebrafish and Drosophila are among the emerging and more interesting model of PD [81].
4.2. Advantages and limitation of modeling PD using drosophila
4.2.1. Advantages
Drosophila offers many advantages for studying human neurodegenerative diseases and their 
underlying molecular and cellular pathology. Benefits include a faster time frame due to the 
shorter life span of the fly (10–14 day from pupae to adult), large number of progeny, avail-
ability of many techniques, and tools to manipulate gene expression [82]. Also Drosophila has 
been studied for longer than any other model out there which makes its anatomy and pheno-
types very well known to experimental biologists [83]. A well developed CNS and prominent 
number of DA neurons [84] combined with well characterized behaviors which are conserved 
among strains in 90% cases [85] makes fly very cost effective and efficient model. Genetically, 
it has been estimated that nearly 75% of disease-related genes in humans have functional 
orthologs in the fly [86]. While overall similarity at nucleotide or protein level is 40% but in 
conserved domain it is 80–90% or higher [87].
4.2.2. Disadvantages
The major difference being an invertebrate there will be some prominent difference in physiol-
ogy with human (e.g., brain anatomy, cardio vascular system, and respiratory system) which 
relating complex motor behavior with human a difficult task [88]. For CNS-related studies, 
there is also an issue on blood-brain permeability difference [89]. The metabolic differences 
are also to be considered when studying drug efficacy and toxin-induced disease phenotype.
4.3. Relevance of study of PD in flies
4.3.1. Drosophila mimicking human PD symptoms
Although the physiological difference between human and flies are very prominent core 
pathology observed in human PD can be produced in a very accurate extent by toxin-induced 
or transgenic modification. It is as accurate as area specific and age-dependent DA neuron 
loss as observed in PD condition and hallmark PD biomarker the LB and LN inclusions are 
visible in transgenic system [90]. Drosophila also performs complex behavior such as mating, 
aggression, conditioning to fear, learning and motor behaviors such as flying, climbing, and 
walking [85] which like human are affected by the PD onset and progression. These multi-
tudes of behavior are very much helpful in characterizing different aspects of PD.
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4.4. Physiological attributes of fly brain
Drosophila model of PD has two principle phenotypes: the specific loss of DAergic neurons 
with aging brain and defects in motor behavior. In fly brain, the DA neurons are distributed 
as a group of clusters throughout the brain and project their effect on different behavioral pat-
terns of the fly by different functional areas of the adult brain. Target areas include:
• The mushroom bodies: involved in memory formation and motivation.
• The Central Complex: controls the motor behavior.
The phenomenon of different part of brain controlling different behavior pattern highly 
resembles the mammalian brain (Figure 1) [84].
4.5. Genetic similarity between Drosophila and human
Drsophila shares 61% homology with human genetically. In fact all the familial or sporadic 
genes reported so far in human associated with parkinsonism are available in Drosophila as a 
Figure 1. (A and C) Schematic representation of an adult fly brain with the distribution of DA neurons grouped in 
clusters and arranged with bilateral symmetry (image adapted from Botella et al. [91]). (B and D) Confocal Z-stack of 
TH > mCD8::GFP brain; anti-nc82 immunoreactivity together with GFP labeling reveals dopaminergic neurons in the 
anterior and posterior brain (image adapted from White et al. [84]).
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homolog. But there is no homolog for the gene α-synuclein which produces Lewy bodies and 
Lewy neuritis at the extracellular matrix of brain a hallmark biomarker under PD condition in 
mammalian brain. Nevertheless α-synuclein transgenic models respond very well under PD 
conditions and recapitulate the PD phenotypes. Given (Table 1) are the list of parkinsonian 
genes and their homologs in flies.
5. Gene-environment interaction studies in PD
The identification of PD symptoms subsequent to ingestion of MPTP led to the idea that 
environmental factors could be related to the causes of pathogenesis of the disease. When 
ingested, MPTP is metabolized to neurotoxin MPP+ which was originally developed as an 
herbicide, cyperquat. The chemical structure of MPP+ is similar to that of the widely used 
herbicide paraquat. This finding suggested that exposure to environmental factors such as 
pesticide, herbicides may contribute to human sporadic PD. Over the years, environmental 
factors, including pesticides and herbicides, metals, tobacco and caffeine, head injuries, etc. 
have been largely considered as possible PD risk factors.
Over the last few decades either through genetic or toxin challenges many animal models 
have been developed to study PD. Using Drosophila melanogaster as a model has proved to 
be of great value and has contributed significantly toward understanding the mechanism 
underlying PD pathogenesis. Table 2 illustrates the interaction studies between environmen-
tal toxins and PD genes using Drosophila model.
Gene/protein Inheritance Fly homolog Protein function
α-Synuclein AD None Pre-synaptic protein
Parkin AR Parkin/CG10523 E3 ubiquitin ligase
UCH-L1 unclear Uch/CG4265 E3 ubiquitin hydrolase/ligase
PINK1 AR Pink1/CG4523 Mitochondrial kinase
DJ-1 AR DJ-1a/CG6646
DJ-1b/CG1349
Redox sensor/Chaperone
LRRK2 AD lrrk2/CG5483 Kinase/GTPase
HtrA2 AD HtrA2/CG8486 Mitochondrial pro-apoptotic protease
GBA unclear CG33090 Lysosomal enzyme
POLG unclear tamas/CG8987 Mitochondrial DNA polymerase
Tau unclear tau/CG31057 Microtubule stabilization
Notes: UCH-L1 = ubiquitin carboxyl-terminal esterase L1; PINK1 = PTEN-induced putative kinase 1; LRRK2 = leucine-
rich repeat kinase 2; HtrA2 = high temperature requirement protein A2; GBA = glucocerebrosidase; POLG = polymerase 
gamma; AD = autosomal dominant; AR = autosomal recessive.
Table 1. Showing parkinsonian genes and their fly homologs [92].
Drosophila melanogaster - Model for Recent Advances in Genetics and Therapeutics166
Environmental toxins such as paraquat (herbicide) increases the risk factors for PD and 
this susceptibility is influenced by the genetic background. Fly model exposed to para-
quat shows neurodegenerative symptoms induced by oxidative stress which are similar 
with most behavioral characters of PD. As seen from epidemiological studies, male flies 
are more susceptibility to paraquat toxicity than female flies. Drosophila mutant for dopa-
mine regulating genes show variable susceptibility to paraquat such as mutations which 
increase DA pathway function helps in reducing paraquat neurotoxicity while loss of func-
tion mutations increases susceptibility to paraquat by decreasing dopamine levels. The loss 
of function mutation in negative regulator of DA production (Catecholamines-up (Catsup)) 
acts by delaying the onset of PD symptoms and loss of DA neurons and confers protection 
against paraquat exposure [99]. Drosophila DJ-1 mutants developed motor deficits when 
exposed to paraquat [100]. Loss of function of DJ-1β mutants confers resistance to paraquat 
and lowers mortality of DA neuron and overexpression of DJ-1α in DA neurons, protects 
against paraquat toxicity [95]. Acute paraquat exposure in Drosophila showed elevated lev-
els of oxidative stress markers and mitochondrial dysfunction [101]. Role of ubiquitin pro-
teosome system (UPS) to sporadic PD is not very clear though it is a potential target for PD 
risk associated with pesticide [102]. Data from epidemiological studies show that paraquat 
in addition with maneb or ziram increases PD risk [103]. Drosophila knockdown of E1 ligase 
when exposed to paraquat + maneb showed significant DA neuron loss thus imply syner-
gistic effects of the pesticides on risk for PD [104].
Rotenone exposure suppresses proteasomal activity through ATP depletion thus inhibiting 
mitochondrial function [105]. Parkin through its E3 ligase function offers neuroprotection 
against neuronal insults including rotenone [106]. Rotenone alters parkin solubility increas-
ing intracellular aggregation and S-nitrosylation of parkin [107]. Loss of parkin increases 
rotenone-induced DA cell death in mice [108]. Drosophila shows negative geotaxis character-
istics and rotenone exposure has shown to cause mortality and locomotor defects affecting 
the climbing ability of flies [109]. Rotenone also inhibits learning and memory functions in 
fly and the damage caused shows severe effect than those in α-synuclein A30P mutant [110]. 
Gene/protein Toxin(s) Observations Reference
α-Synuclein Rotenone Drosophila larvae expressing mutant human α-synuclein showed 
significant loss of DA neurons and deficit in locomotion
[93]
DJ-1 Paraquat
Rotenone
DJ-1 KO flies selectively sensitive to oxidative stress induced by 
toxins
[94]
[95]
LRRK2 Rotenone hLRRk2 transgenic flies showed loss of DA neurons and sensitivity 
to environmental toxin
[96]
Parkin Rotenone Transgenic flies expressing parkin mutation show age-dependent 
DA neuron degeneration and locomotor deficits
[97]
PINK1 Rotenone Flies expressing PINK1 mutations show increased rates of mortality 
in the mutants
[98]
Table 2. Gene-environment interaction studies in drosophila model of PD.
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Exposure of adult Drosophila to sublethal doses of rotenone causes concentration-dependent 
locomotor deficiencies, specific dopaminergic neuronal loss, and reduction in the DA levels in 
flies [111]. Non-motor symptoms such as circadian rhythms in Drosophila are also altered fol-
lowing exposure to rotenone [112]. All these studies highlight the utility of drosophila model 
to understand the gene-environment interaction in PD.
5.1. Drosophila PD models and associated tools
Drosophila is proved to be one of the important genetic models to study the disease mechanism 
in PD. Even though with limitations, the fly model enables rapid and elaborate genetic study, 
providing in depth cell and molecular studies which offers a unique look into the mechanisms 
and pathways underlying PD pathogenesis [113]. Currently 14 genes for PD have been identi-
fied of which 12 genes have homology with Drosphila. Loss of function and gain of function 
analysis using fly model would provide insights into the mechanism of action of these genes 
associated with PD (Table 3).
5.2. Mitochondrial genetics of PD: insights from drosophila model
Drosophila model has made major contribution in the research area of mitochondrial genet-
ics. The early hints of PINK1/parkin on mitochondrial homeostasis came from studies using 
Drosophila model [98, 114, 115]. The most compelling evidence for a mitochondrial etiology of 
Gene/symbol Drosophila 
homolog
(Over)Expression 
construct
(Over)Expression 
construct with point 
mutation
Loss of function 
mutants
SNCA/ PARK1 No YES YES NO
PARK2 encoding parkin/ PARK2 Parkin YES YES YES
UCHL1/PARK5 Uch NO NO NO
PINK1/PARK6 Pink1 YES YES YES
PARK7 encoding DJ1/PARK7 Dj-1α and Dj-1β YES NO YES
LRRK2/PARK8 Lrrk YES YES YES
ATP13A2/PARK9 CG32000 YES NO NO
HTRA2/PARK13 Htra2 YES YES YES
PLA2G6/PARK14 iPLA2-VIA NO NO YES
FBOX7/PARK15 No homolog YES YES NO
VPS35/PARK17 Vps35 YES Yes YES
EIG4G1/PARK18 eIF4G No NO NO
DNAJC6/PARK19 auxillin YES NO YES
SYNJ1/PARK20 Synj YES YES NO
Table 3. Drosophila model of Parkinson’s disease (genetic) (adapted from Vanhauwaert and Verstreken [113]).
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PD was derived from the study of genes mediating familial forms of the disease in fly model 
[116, 117]. Mutations in Pink1 (PARK6), which encodes a serine-threonine kinase localized 
to mitochondria and parkin (PARK2), which encodes a RING finger-containing E3 ubiquitin 
ligase have been found in recessively inherited and sporadic PD cases [56, 118]. Drosophila 
PINK1 and parkin function in the same genetic pathway, with pink1 acting upstream of par-
kin, to regulate mitochondrial integrity in testes, muscle, and dopaminergic neurons [98, 115, 
119]. Flies lacking PINK1 or parkin function are viable and show muscle degeneration and 
TUNEL staining, indicative of cell death [98, 115, 119]. Parkin and PINK1 mutant flies show 
locomotor defects, abnormal wing position, and dented thoraces [98, 115, 119]. Mitochondrial 
defects seen in parkin or PINK1 mutant flies are majorly found in the muscle cells though 
other cell types like DA neurons in the fly brain also show mitochondrial defects which sug-
gests that loss of PINK1 or parkin would result in systemic mitochondrial defects but not 
extended to all tissues with similar extent [98, 115, 119]. PINK1 and parkin mutant flies show 
very similar phenotypes suggesting that these genes act together in protecting mitochondria 
from damage. Drosophila expressing wild-type parkin in a PINK1 mutant partially rescues 
PINK1-associated phenotypes. Alternatively, PINK1 wild type expression in a parkin mutant 
does not rescue the parkin-associated phenotypes which shows that parkin acts downstream 
of PINK1 [98, 115]. Parkin is also associated with degradation of mitochondria by autophagy 
and proteasomal degradation of mitochondrial components [113, 120].
Mitochondrial DNA mutations were first associated with different sporadic or maternally 
inherited neuromuscular disorders [121]. These disorders were characterized by either the 
accumulation of multiple mtDNA deletions in post-mitotic tissues [122] or tissue-specific 
mtDNA depletion [123], and a genetic defect affecting nuclear genes involved in mtDNA rep-
lication and maintenance [124]. Mitochondrial DNA often exists in a state of heteroplasmy 
(cells carrying mtDNA of different genotypes), in which mutant mtDNA co-exists in cells with 
wild-type mtDNA. Pathology is seen when the frequency of such a mutation reaches a thresh-
old [125]. It accumulates throughout life and is thought to contribute to diseases of aging 
that include neurodegeneration, metabolic disorders, cancer, heart disease, and sarcopenia 
[126, 127]. A new investigation of mtDNA in the dopaminergic neurons [128] expanded the 
previous results showing a prevalent deletion in single neurons on a background of multiple 
mtDNA deletions [129]. It showed that complex I and complex II are most consistently affected 
in single neurons, which also displayed a reduced mtDNA copy number [128]. Stimulation of 
autophagy, activation of the PINK1/parkin pathway, or decreased levels of mitofusin results 
in a selective decrease in lethal mtDNA deletion [130]. Similar to flies lacking parkin, the flies 
with mtDNA deletions display striking mitochondrial abnormalities such as disrupted cristae 
resulting in reduced ATP levels leading to apoptosis and subsequently neurodegeneration.
These dynamic processes regulate mitochondrial function by enabling mitochondrial recruit-
ment to critical subcellular compartments, content exchange between mitochondria, mito-
chondrial shape control, mitochondrial communication with the cytosol, and mitochondrial 
quality control making the mitochondria readily adapt to changes in cellular requirements. 
When mitochondrial dynamics is disrupted, cellular dysfunction follows. The view of mito-
chondrial dynamics has expanded from a curious phenomenon into an integral cell biological 
process influencing many cellular functions and survival [131].
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5.3. Mitochondrial dynamics: fusion and fission
Mitochondria undergo frequent fission and fusion events contributing to the filamentous and 
interconnected morphology of the organelles and serve crucial physiological functions [132]. 
The first mitofusin was discovered in mutant Drosophila characterized by male sterility [133]. 
During cell division, mitochondrial fission plays an important role for proper inheritance 
of mitochondria to the daughter cells. Moreover, organelle fission appears to be important 
to meet the energy demands of cells at particular subcellular locations. This is true espe-
cially for neurons, which heavily depend on energy supply, where mitochondria can travel 
via microtubule-associated motor proteins to serve specialized neuronal functions such as 
synaptic transmission. Furthermore, an interconnected network of contiguous mitochondrial 
organelles seems to be required for the intramitochondrial exchange of metabolic substrates 
as well as the maintenance of respiratory capacity and mitochondrial membrane potential in 
hypoxic cellular regions [134].
Mitochondrial fission and fusion events are regulated and coordinated by evolutionarily 
highly conserved molecular machineries. The molecules regulating mitochondrial dynamics 
include the homologous GTPases Mitofusin 1 (Mfn1) and Mitofusin 2 (Mfn2), which mediate 
fusion of the mitochondrial outer membrane, and Optic atrophy 1 (Opa1), a GTPase required 
for fusion of the inner membrane. Mitochondrial fission, conversely, requires Dynamin-
related protein 1 (Drp1), which is also a GTPase [131, 135]. The Drosophila melanogaster genome 
encodes two homologs of Mfn, one being Fuzzy onion (Fzo) [133]. The expression of Fzo is 
restricted to the testes, and mutations in fzo causes mitochondrial fusion defects in testes and 
male sterility [133]. The second Drosophila Mfn homolog is a largely uncharacterized protein 
known as mitochondrial assembly regulatory factor (Marf), which is expressed in germline 
and somatic cells [136]. The Drosophila genome also encodes single homologs of opa1 [137] 
and drp1 [138], both of which have been shown to function in mitochondrial dynamics in flies.
5.4. Genome-wide association studies (GWAS) and genetic screens
GWAS are large-scale population-based genotyping studies that were designed to capture 
common genetic risk loci and searches for small variations, called single nucleotide poly-
morphisms or SNPs, which occur more frequently in people with particular disease than in 
people without the disease. These approaches lead to the identification of new disease caus-
ing genes, new biological pathways to explain disease origin or progression, and potential 
therapeutic targets which is much more precise than the corresponding information from 
linkage-based studies.
Maraganore and colleagues conducted the first GWAS for PD. It had limited sample sizes (few 
hundred patients) and patient-control series were sometimes mismatched, but they remain in 
the genetic history of PD and suggested the low heritability of PD generating a large amount 
of genetic data into public domain to be further examined and completed by other researchers 
[139]. Over the last two decades, human GWAS have begun to reveal the genetic risk factors 
for countless common disorders with complex genetic etiologies including most of the major 
causes of morbidity and mortality in the developed world [140].
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Involvement of multiple genes and pathways complicate the identifying and developing effec-
tive therapeutic strategies in different geographical and ethnically divergent populations. Here 
lies the necessity and importance of GWAS relating to complex neurological disorders such 
as PD and cancers. Mutations in five genes have been identified to contribute to Mendelian 
forms of PD risk in fewer than 5% of those with PD which suggest that additional genes too 
contribute to disease risk [141]. In 2009, two GWAS papers provided unequivocal evidence for 
an association of the MAPT locus and SNCA variations with sporadic PD. Additionally, both 
papers implicated variants close to LRRK2 and at two new loci on chromosome 1 (1q32) and 
chromosome 4, close to the bone marrow stromal cell antigen 1 (BST1) gene [142]. Shortly after 
these findings, Pankratz et al. conducted the first GWAS in familial PD, confirming the previ-
ous discoveries and providing preliminary evidence for an association of a new locus contain-
ing the genes cyclin G association kinase (GAK) and diacylglycerol kinase theta (DGKQ) with 
PD [142, 143]. A meta-analysis on more than seven million polymorphisms originating either 
from GWAS datasets and/or from smaller scale PD association studies was performed, where 
10 loci showed genome-wide significant association with PD risk (BST1, CCDCC2/HIP1R, 
DGKQ/GAK, GBA, LRRK2, MAPT, MCCC1/LAMP3, SNCA, STK39, and SYT11/RAB25) and 
novel evidence for genome-wide significant association with polymorphism in STGA8 was 
found [144]. To date, the largest GWAS was performed in 2014 carrying out a meta-analysis in 
all existing European-ancestry PD GWAS data with 13,708 PD cases, 95,282 controls and a rep-
lication study using genotyping array called ‘Neuro X’ in an independent data set identified 
26 independent SNPs which showed genome-wide risk for PD [145].The first papers about the 
potential impact of risk loci on age at onset (AAO) in PD were published in 2015. The results 
using polygenic score analysis showed that patients with an early AAO had a significantly 
higher polygenic score when compared to those with late AAO [146]. GWAS showed a genetic 
association with PD in the HLA region (chromosome 6p21.3), which was designated PARK18 
and the common variant associated with late onset sporadic PD was rs3129882 in intron 1 of 
HLA-DRA [147] GWAS sporadic PD was performed and sterol regulatory element binding 
transcription factor 1 (SREBF1) was identified as risk factor for PD [148]. Later, an unbiased 
approach on genome-wide RNAi screen was performed in Drosophila cells and validated in 
Hela cells to identify genes regulating the PINK1/parkin pathway, which act in a common 
genetic pathway in mediating the autophagic degradation of mitochondria (mitophagy) and 
found 20 genes that have a conserved function in promoting translocation and degradation of 
depolarized mitochondria. But most notable genes involved were (SREBF1) Fbox and WD40 
domain protein 7 (FBXW7), and other components of the sterol regulatory element binding 
protein (SREBP) lipogenesis pathway indicating a role of lipids in mitochondrial homeostasis, 
which further showed that this pathway regulate mitophagy and also share a common mecha-
nistic link between autosomal-recessive and sporadic PD [149].
The loci currently associated with PD account for only a very small amount (3–5%) of the 
expected heritability of PD, suggesting that additional heritable factors (genetic or epigenetic) 
also play a role in transforming susceptibility to PD. While current evidence suggests that 
common genetic variants play a role in the etiology of typical PD. GWAS by their inherent 
design may not be able to detect rare variants [143, 150]. Most SNPs detected by GWAS are 
not likely causal variants for disease risk but rather informative markers hence it is often not 
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productive to study their direct functional consequences. Also cases selected for GWAS may 
not be particularly enhanced with genetic susceptibility alleles, moreover the effect sizes iden-
tified for most variants are reduced. Thus multiple approaches including linkage analysis, 
sequencing, and sibpair analysis would be needed to discover additional variants/causative 
genes and susceptibility loci. Large-scale genome and exome sequencing in conjunction with 
denser genotyping in large cohorts may help to identify the loci that contribute to the “miss-
ing heritability” previously unnoticed by earlier generation technologies [151].
6. Utilizing Drosophila to understand human GWAS signals
6.1. GAL4-UAS system
In 1993, Brand and Perrimon developed the GAL4-UAS system for precise spatial and temporal 
patterns directing gene expression in Drosophila and has been considered as a powerful research 
tool. A bipartite approach in which a transcriptional activator, the GAL4 gene binds to specific 
cis-enhancer elements, upstream activation sequence (UAS) leading to activation of the adjacent 
gene, and thousands of GAL4 driver lines available from individual labs and public stock col-
lections allow expression of desired target genes, typically cDNA transgenes under control of 
upstream activating sequence (UAS) sites [152]. Findings showed that several familial forms of 
parkinsonism result from increased gene dosage of α-syn, based on this expression levels of the 
α-syn transgene was augmented by generating an α-syn expression construct bearing sequence 
alterations designed to improve the translational efficiency of this cDNA in Drosophila and fur-
ther maximized α-syn protein expression in the fly brain by making use of flies bearing two 
copies each of the UAS-α-syn transgene and the TH-GAL4 driver; these control approximately 
doubled the abundance of α-syn protein relative to flies bearing a single copy of each of these 
transgenes generating a more robust Drosophila model for studying synucleinopathies [153].
6.2. RNA interference (RNAi)
RNAi is an RNA-dependent gene-silencing process that is regulated by the RNA-induced 
silencing complex (RISC) and triggered by short double-stranded RNA (dsRNA) molecules.
Efficient silencing of gene expression by dsRNA was first discovered by Fire and Mello [154]. 
RNAi silencing of a specific target gene relies on the ability of small interfering RNAs (siR-
NAs), long double-stranded RNAs (dsRNAs), or short hairpin RNAs (shRNAs) to target 
mRNA molecules for degradation [155–157]. Drosophila in vivo RNAi techniques screen both 
the whole genome and subsets of genes. A total of 10,689 different genes (78% of the Drosophila 
genome) were assayed that affect susceptibility to intestinal Serratia marcescens infection [158]. 
Of these, 8.3% (885 genes) were defined as hits; the majority 89.3% (790 genes) were suscep-
tibility candidates, and 95 genes (10.7% of hits) were negative regulators. A total of 78 and 56 
genes were found to function only in the gut and hemocytes, respectively, and 79 functioned 
in both. A primary screened of 6923 UAS-IR strains for genes involved in the glycosylation 
of a neural glycoprotein and identified 171candidates [159]. These were further confirmed by 
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knock down experiments, using in-silico analysis and a secondary set of UAS-IR strains that 
targeted regions distinct from those of the primary strains. A total of 2970 genes were knocked 
down by neuron-specific RNAi in search for genes involved in the formation, growth, and 
maintenance of the neuromuscular junction (NMJ) [160]. Knockdown of 158 genes in post-
mitotic neurons led to abnormalities in the neuromuscular system. Genome-wide small 
interfering RNA (siRNA) screening yielded gene candidates involved in characterization 
of TOMM7 required for stabilizing PINK1 on the outer mitochondrial membrane follow-
ing mitochondrial damage. Also, HSPA1L (HSP70 family member) and BAG4 found to have 
mutually opposing roles in the regulation of parkin translocation. RNAi screens revealed that 
SIAH3 localize to mitochondria, inhibits PINK1 accumulation after mitochondrial insult, and 
reducing parkin translocation. Overall, screens provide a rich resource to understand mito-
chondrial quality control [161].
Using this inducible RNAi technique, large-scale screens for various biological processes have 
been performed successfully in Drosophila, proving RNAi-based in vivo screen adequate and 
efficient. However, RNAi-based screens have relatively high levels of false positives and neg-
atives. To validate the screening results, experimental, and computational analyses have been 
proposed which will increase the accuracy of RNAi-based screen results.
6.3. CRISPR/Cas9
Clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/
Cas9) was first applied in mammalian cells in 2013 which has been used as an essential tool in 
biotechnology [162]. The CRISPR/Cas9 system is a novel genome modification method in which 
gRNA direct the nuclease Cas9 to selected sequences of genomic DNA, and Cas9 cuts both 
strands at a specific location. Non-homologous end joining (NHEJ) or homology-directed repair 
(HDR) repairs the genomic DNA resulting in mutations that can interrupt the open reading 
frame and cause gene inactivation. For example, loss in function of parkin and Pink1 genes 
causes PD, CRISPR/Cas9-mediated mutations can mimic knockout of the parkin and/or Pink1 
gene [163]. Thus, when both alleles are mutated by CIRSPR/Cas9, the complete loss of parkin 
or Pink1 will mimic the genetic mutations in PD patients. Indeed, CRISPR/Cas9 has been used 
to generate pig models of PD by targeting the genes for parkin, Pink1, and DJ1 [164]. In addi-
tion to genome editing in germline cells, CRISPR/Cas9 can efficiently target genes in somatic 
tissues, such as neurons in the brain [165, 166]. In PD patients, continuous loss of dopaminergic 
neurons in the substantia nigra is a fundamental pathological feature. Thus, gRNAs and Cas9 
can be delivered to the substantia nigra of animal brains by a viral system to examine the effect 
of parkin or Pink1 loss in adult brains. This approach is especially useful for investigating the 
age-related neuropathology in PD. Also, by gaining toxicity of mutant proteins Cas9-mediated 
knock-in mutations within the genome can develop animal models of those neurodegenerative 
diseases.
For transgenic PD animal models that express mutant a-syn, CRISPR/Cas9 can be designed 
to reduce the expression of mutant genes via NHEJ, which can lead to gene inactivation, in 
dopaminergic neurons. Besides, replacing the mutant gene by CRISPR/Cas9 via HDR with 
normal DNA sequences can also lead to the genetic correction of DNA mutations in PD animal 
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models. Even though efficiency of such gene replacement is low at present, the rapid devel-
opment of CRISPR/Cas9 system offers a promising attempt to produce knock-in models of 
human diseases [167].
6.4. Deciphering the pathways of therapeutic molecules: role of drosophila model
The first published study about compound treatments in a drosophila PD model reported the 
effects of drugs commonly used for treating PD on the locomotor phenotype of α-synuclein 
expressing flies and showed that some of them were able to suppress that phenotype [168]. 
Subsequently, and given the ability of increased chaperone activity to counteract α-synuclein 
toxicity [169], the effect of geldanamycin (GA), an antibiotic able to interfere with Hsp90 activity 
and activate stress response, was assayed over α-synuclein expressing flies [170, 171]. Notably, 
feeding these flies with GA protected DA neurons against α-synuclein-induced degeneration, 
and this protection was driven by an increase in Hsp70 levels [171]. Inhibitors of the histone 
deacetylase SIRT2 also showed a protective effect against α-synuclein toxicity [172]. Other 
studies have been also performed in several drosophila PD models to look for potentially ther-
apeutic compounds directed to reduce oxidative stress damage. As explained previously, the 
study of α-synuclein toxicity in flies led to the identification of Phase II detoxification pathway 
as a possible target for therapeutic treatment [173]. In fact, feeding α-synuclein-expressing flies 
or Drosophila parkin mutants with pharmacological inducers of that pathway like sulforaphane 
or allyl disulfide suppresses the neuronal loss of both PD models [173]. Besides, it has been 
shown that dietary supplementation with S-methyl-L-cysteine (SMLC) inhibits the locomo-
tor and circadian rhythm defects caused by ectopic expression of human α-synuclein in dro-
sophila [174]. SMLC participates in the catalytic antioxidant mechanism involving methionine 
sulfoxide reductase A (MSRA), one of the enzymes that catalyze the oxidation of the amino 
acid methionine to methionine sulfoxide, a reversible reaction that has been postulated to act 
protecting cells from oxidative damage. Furthermore, grape extract supplementation has been 
shown to recover locomotor ability and lifespan in α-synuclein-expressing flies. It is known 
that grape extracts contain several polyphenols, compounds with antioxidant properties [175]. 
Other drosophila PD models in which treatments with antioxidant compounds have been 
shown to be beneficial are those involving the DJ-1α and DJ-1β genes [176, 177]. Compounds 
with antioxidant and anti-inflammatory properties such as celastrol and minocycline con-
ferred potent DA neuroprotection in RNAi DJ-1α mutants [176]. We have also recently dem-
onstrated that chronic treatments with antioxidant compounds are able to modify the lifespan 
phenotype of DJ-1β mutant flies, thus suggesting that oxidative stress plays a causal role in 
such phenotype [177]. It is known that rapamycin is a small molecule inhibitor of TOR signal-
ing that has been shown to lead to 4E–BP hypophosphorylation in vitro and in vivo [178, 179]. 
Notably administration of rapamycin was able to suppress all pathologic phenotypes in parkin 
and PINK1 mutants. Moreover, this suppression was found to be 4E-BP dependent, since the 
administration of rapamycin to parkin and Thor or PINK1 and Thor double mutants was com-
pletely unable to suppress these phenotypes [180]. Since 4E-BP activity can be manipulated 
by small molecule inhibitors such as rapamycin, this pathway represents a viable therapeutic 
target for PD treatment. Moreover, it has been recently suggested that parkin mutants, apart 
from the described phenotypes, also present altered zinc homeostasis. This is supported by 
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the fact that dietary zinc supplementation in the form of zinc chloride increased lifespan as 
well as the percentage of parkin mutant flies reaching adulthood while this supplemented diet 
was deleterious to control flies [181]. Since most PD cases are sporadic and could be associ-
ated to different environmental agents, it is also essential the use of toxin-induced drosophila 
PD models to assay the beneficial effects of candidate compounds. Polyphenol administration 
was also found to exert a beneficial effect on flies exposed to paraquat and iron, protecting, 
rescuing, and restoring the impaired locomotor activity caused by exposure to those agents 
[182]. Other antioxidant compounds such as melatonin have also been found to rescue loco-
motor deficits and DA neurodegeneration in flies exposed to rotenone [19].
6.4.1. LRRK2 kinase inhibitors
Several LRRK2 kinase inhibitors, including CZC-25146, GW5074, and sorafenib, have been 
tested in rodents, as well as in Caenorhabditis elegans and drosophila models, and have been 
shown to protect against LRRK 2 (G2019S)-induced neurodegeneration [183]. These findings 
indicate that increased kinase activity of LRRK2 is neurotoxic and that inhibition of LRRK2 
activity can have a disease-modifying effect.
6.4.2. Molecular chaperones
6.4.2.1. HSF-1 modulators
Endogenous molecular chaperone function can be modulated pharmacologically with com-
pounds that augment endogenous chaperone levels. Several HSF-1 modulators including 
celastrol and carbenoxolone can trigger HSF-1 activation, leading to downstream induction 
of Hsp70 expression [184]. Celastrol has been demonstrated to be effective against protein 
aggregation and toxicity in various neurodegenerative disease models, including dopaminer-
gic neuroprotection in a Drosophila model of PD [176]. Carbenoxolone has demonstrated the 
ability to attenuate 𝛼-synuclein and ubiquitin aggregation in vitro and in vivo [185, 186]. Thus, 
it may have potential as a chaperone-mediated therapeutic option for PD. Hsp90 Inhibitors 
a naturally occurring small molecule antibiotic, geldanamycin (GA), inhibits the interaction 
between Hsp90 and HSF-1, leading to increased Hsp70 expression [187]. In vitro cell studies 
have demonstrated the capability of this compound to decrease 𝛼-synuclein aggregation and 
reduce cell toxicity [188], and its neuroprotective effects have been shown in Drosophila and 
MPTP mouse models of PD [169, 189]. Other analogues of GA include 17-AAG and 17-DMAG, 
which similarly prevent 𝛼-synuclein aggregation and toxicity, but are more potent and less 
toxic than GA [190]. Moreover, 17-AAG has poor permeability of the BBB, limiting its phar-
macological usage for neurodegenerative diseases [185]. Consequently, compound library 
screening for small molecule Hsp90 inhibitors with improved pharmacokinetics, including 
BBB permeability, have led to the identification of SNX compounds [185]. These compounds 
are associated with an increase in Hsp70 activity in the brain and a reduction in 𝛼-synuclein 
oligomerization and toxicity in vitro [190].
Insights regarding identification of pathways through which different therapeutic molecules 
confer neuroprotection is briefed in Table 4.
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Pathway/process Compound treatment* Drosophila model Modified phenotype/s References
Oxidative stress Sulforaphane and allyl 
disulfide*
S-methyl-Lcysteine
Polyphenols
α-tocopherol
SOD
Melatonin
Bacopa monieri
leaf extract
Parkin
α-synuclein
α-synuclein
α-synuclein
Paraquat and iron
DJ-1β
PINK1
PINK1
DJ-1β
Paraquat
Rotenone
Paraquat
DA neuron number
DA neuron number
Locomotor activity
Lifespan, locomotor 
activity
Locomotor activity
Lifespan
Ommatidial 
degeneration
Ommatidial 
degeneration
Lifespan
Locomotor activity
Locomotor activity, DA 
neuron
Oxidative markers levels
[173]
[173]
[174]
[175]
[182]
[177]
[191]
[191]
[177]
[99]
[99]
[192]
Oxidative stress/
inflammatory process
Minocycline*
Celastrol
DJ-1α DA neuron number, 
dopamine Levels
DA neuron number, 
dopamine levels, 
locomotor activity, and
survival rate under 
oxidativestress condition
[176]
TOR signaling Rapamycin* parkin/PINK1 Thoracic indentations, 
locomotors activity, DA 
neuron number, and 
muscle integrity
[180]
Removal of excess or toxic 
protein forms
Geldanamycin* α-synuclein DA neuron number [170]
[171]
Zinc homeostasis Zinc chloride* parkin Lifespan, locomotor 
activity, and percentage 
of adulthood
survivors
[181]
Chaperone therapies (HSF-1 
modulators)
Trigger HSF-1 activation
Induces downstream Hsp70 
expression
Celastrol
Carbenoxolone
α-synuclein
α-synuclein
dopaminergic 
neuroprotection
[184]
Hsp90 inhibitors
Inhibits the interaction 
between Hsp90 and HSF-1, 
leading to increased Hsp70 
expression and activity
Geldanamycin
17-AAG
17-DMAG
SNX-2112
α-synuclein decrease α- synuclein 
aggregation and reduce 
cell toxicity
[187]
[190]
mTOR-dependent 
pathways/AMPK
Metformin
AICAR
Drosophila 
melanogaster
mutated for LRRK2
Reduced cell death [193]
mTORC1 Rapamycin and Rp 
analogues
(CCI-779, RAD001 and 
AP23573)
Drosophila 
melanogaster
mutated for PINK-1 
and
Parkin
Reduced mitochondrial
Dysfunction
[180]
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7. Conclusion
Bench to bedside: role of drosophila in translational research.
Bench to bedside is a term used to describe the process by which the results of research done 
in the laboratory are directly used to develop new ways to treat patients. Taking advantage 
of studies from animal models such as drosophila certain pharmacotherapies and non-phar-
macotherapies have been developed which are in different stages in clinical trials to validate 
their efficacy, safety, and tolerability. Pharmacotherapies include adenosine A2A receptor 
antagonists [196], glutamate AMPA receptor antagonists [197], monoamine oxidase inhibitors 
[198], anti-apoptotic agents [199], and antioxidants [200]. Non-pharmacotherapies also offer 
alternative approaches for treatment of the disease which include the use of viral vector gene 
therapy [201], stem cell transplants [202], and microRNAs [203]. Nevertheless, additional tri-
als enrolling larger numbers of PD patients are still needed to better understand the neuro-
protective effects of these therapies.
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Pathway/process Compound treatment* Drosophila model Modified phenotype/s References
mTor-independent 
pathways/unknown
Spermidine α-synuclein Reduced motor 
dysfunction,
increased lifespan; 
Reduced
neuronal cell loss
[194]
LRKK2 kinase inhibitors GW5074, and sorafenib α-synuclein Protect again DA neuron 
degeneration
locomotor activity
[183]
Histone Deacetylase 
inhibitors
α-synuclein Protect again DA
locomotor activity
[195]
Antitumor agents Geldanamycin α-synuclein Protect again DA
Mobilized the stress 
response and increase 
levels of chaperon 
HSP70
[195]
*All treatments were administered as dietary complement.
Table 4. Listing of pathways through which neuroprotective compounds confer neuroprotection: lessons from drosophila 
model of PD.
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